A Phase 2a, Randomized, Double-blind, Sponsor Unblinded, Placebo-controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Subjects With Active Ulcerative Colitis
A Phase 2a, Randomized, Double-blind, Sponsor Unblinded, Placebo-controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Subjects With Active Ulcerative Colitis
This study represents the first investigation of anrukinzumab in patients with active ulcerative colitis (UC) and will evaluate proof of mechanism by changes in the mechanism based biomarker (YKL 40) and pharmacodynamic biomarkers (fecal calprotectin, lactoferrin and hs-CRP). It will provide further assessment of the safety, tolerability, and pharmacokinetics (PK) by administration of multiple intravenous (IV) doses of anrukinzumab.
Inclusion Criteria:
Exclusion Criteria:
Cleveland, Ohio 44106, United States
Round Rocks, Texas 78681, United States
Rousse, 7002, Bulgaria
Sofia, 1606, Bulgaria
Vancouver, British Columbia V5Z 1M9, Canada
Kingston, Ontario K7L 5G2, Canada
Budapest, 1125, Hungary
Amsterdam, 1105 AZ, Netherlands
Warsaw, 02-507, Poland